Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis)
Two synthetic cannabinoid tablets, dronabinol and nabilone, have been approved for chemotherapy nausea since 1985 and can help when standard anti-sickness drugs fail. Modern antiemetics work better for most people, and evidence for herbal cannabis or vaped products is thin.
Overview
Dronabinol (synthetic THC) and nabilone were approved by the FDA in 1985 for chemotherapy-induced nausea and vomiting refractory to conventional antiemetics. Trials from that era showed superiority over placebo and prochlorperazine, at the price of dizziness, dysphoria and sedation; there are no adequate head-to-head trials against 5-HT3 antagonists, NK1 antagonists or olanzapine, which are now first-line. ASCO and MASCC/ESMO antiemetic guidelines list FDA-approved cannabinoids as an option for breakthrough or refractory nausea. A 2024 randomised trial from Australia found an oral THC:CBD extract added to standard antiemetics reduced refractory nausea, a signal the 2024 ASCO cannabis guideline cites while noting the evidence for herbal cannabis remains limited. Smoked or vaped cannabis has not been adequately tested and carries respiratory and psychoactive risks. Cannabinoids can also cause cannabinoid hyperemesis with heavy chronic use.
How it works
THC activates CB1 receptors in the dorsal vagal complex and area postrema, suppressing emetic signalling; CBD may act via 5-HT1A.
- Approved drugs with randomised evidence versus placebo
- Option for refractory nausea
- Addressed in ASCO and MASCC guidance
- Not compared with modern antiemetics
- Psychoactive side effects, especially in older adults
- Herbal and vaped products under-studied
Latest papers
topQuery for this technology: (TITLE:"Cannabinoids for chemotherapy nausea" OR ABSTRACT:"Cannabinoids for chemotherapy nausea" OR TITLE:"dronabinol, nabilone, medical cannabis" OR ABSTRACT:"dronabinol, nabilone, medical cannabis") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis), not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyGinger for chemotherapy nausea
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Evidence-based integrative oncology, Toxicity and quality of life are undervalued and the tags complementary, supportive-care, evidence:moderate.
- TechnologyAcupuncture and acupressure for chemotherapy nausea
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Evidence-based integrative oncology, Toxicity and quality of life are undervalued and the tags complementary, supportive-care, evidence:moderate.
- TechnologyAmerican ginseng for cancer-related fatigue
Shares Evidence-based integrative oncology, Toxicity and quality of life are undervalued and the tags complementary, supportive-care, evidence:moderate.
- TechnologyAcupuncture for dry mouth after head and neck radiotherapy
Shares Evidence-based integrative oncology, Toxicity and quality of life are undervalued and the tags complementary, supportive-care, evidence:moderate.
- TechnologyRelaxation training and guided imagery
Shares Evidence-based integrative oncology, Toxicity and quality of life are undervalued and the tags complementary, supportive-care, evidence:moderate.
- TechnologyProbiotics for chemotherapy and radiotherapy diarrhoea
Shares Evidence-based integrative oncology, Toxicity and quality of life are undervalued and the tags complementary, supportive-care, evidence:moderate.
- TechnologyMusic therapy and music medicine
Shares Evidence-based integrative oncology, Toxicity and quality of life are undervalued and the tags complementary, supportive-care, evidence:moderate.
- TechnologyClinical hypnosis for procedures, pain and hot flushes
Shares Evidence-based integrative oncology, Toxicity and quality of life are undervalued and the tags complementary, supportive-care, evidence:moderate.